Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Sub-Myeloablative Allo-SCT for Hematologic Malignancies
NCT00069992Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2001
- Primary completion
- Sep 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), sponsored by Baylor College of Medicine. Started Dec 2001; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00069992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069992.